WEBULL
WebtradeDownload

Intuitive Surgical (ISRG) Gains A New Europe Approval Following A Fresh Undervalued View

Simply Wall St · 15h ago

Intuitive Surgical (ISRG) just received CE mark approval for using its da Vinci SP system in transvaginal gynecologic procedures, a first-of-its-kind indication that expands the robot’s minimally invasive surgery footprint in Europe.

Recent moves show momentum starting to rebuild. The 30 day share price return of 8.74% and recent 1 day gain came after a weak year to date share price return that declined 27.9%. However, the 3 year total shareholder return of 37.36% remains positive for Intuitive Surgical.

Scan how Intuitive Surgical fits into the broader robotics and automation story by comparing it with the hand-picked companies in 92 robotics and automation stocks.

The rebound in Intuitive Surgical after a weak year to date slide raises a simple tension. Is the recent strength mostly a catch up in sentiment, or a clear reflection of the underlying business, and what does that imply for valuation?

Most Popular Narrative: 15% Undervalued

Intuitive Surgical closed at $405.18, compared with a widely followed fair value estimate of $476.34 that uses a 7.49% discount rate and leans heavily on procedure growth and platform expansion to justify that gap.

Ion’s 36% procedure growth in Q2 2026 to 48,000 quarterly procedures, with systems already installed in 12 countries outside the U.S., shows a second platform gaining traction that can diversify Intuitive Surgical’s revenue base, add incremental recurring instrument and accessory revenue, and contribute to long term operating margin support.

See why 236 investors see Intuitive Surgical as 15% undervalued.

Result: Fair Value of $476.34 (UNDERVALUED)

Still, the Intuitive Surgical story can break if budget pressure in markets like China limits new systems, or if Johnson & Johnson’s robot reduces its pricing power.

Find out about the key risks to this Intuitive Surgical narrative.

Another View: Intuitive Surgical Through The P/E Lens

Step away from the fair value estimate and Intuitive Surgical looks different when viewed through its P/E ratio. The stock trades at 45.6x earnings, while the US Medical Equipment industry sits at 25.2x and peers average 24.9x. The fair ratio is 35.8x, a level the market could move toward over time.

That gap points to clear valuation risk if sentiment cools, even with a strong business story in the background. It raises a simple question for investors: Is the current premium multiple a fair price for quality, or is it stretching what the fundamentals justify? See what the numbers say about this price — find out in our valuation breakdown.

NasdaqGS:ISRG P/E Ratio as at Sep 2026
NasdaqGS:ISRG P/E Ratio as at Sep 2026

Next Steps

If this mix of optimism and caution around Intuitive Surgical resonates with you, consider acting while the data is fresh and pressure test it yourself through 3 key rewards.

Looking for more Intuitive Surgical investment ideas?

Do not stop with Intuitive Surgical alone. Broaden your watchlist with fresh, data backed ideas that could round out your portfolio and reduce single stock reliance.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.